source
- BrainChild secures $116M to advance CAR-T therapies for rare pediatric brain tumorsBrainChild Bio, a Seattle‑based biotech spun out of Seattle Children’s Hospital, announced it has raised $116 million in venture financing. The capital will fund the development of its CAR‑T cell t…
- BrainChild Bio raises $116 million to fund pivotal pediatric brain tumor CAR-T trialBrainChild Bio, a Seattle-based biotech, announced it has secured $116 million in financing to support a pivotal clinical trial of its CAR-T therapy aimed at pediatric brain tumors. The funding ro…